3 Monster Stocks to Hold for the Next 10 Years

The article recommends three healthcare stocks as long-term investments: Eli Lilly, benefiting from the high-growth weight loss drug market; AbbVie, successfully transitioning from Humira patent expiration with new immunology drugs; and Abbott Laboratories, offering diversification across medical devices, diagnostics, nutrition, and pharmaceuticals. These established companies are positioned for sustained growth over the next decade.

06/23/2026, 6:05 AM • The Motley Fool

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accretive by 2032 and support AbbVie's dividend yield of over 3%.

06/22/2026, 6:36 PM • The Motley Fool

Should You Buy Moderna Before Aug. 5?

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.

06/22/2026, 6:10 PM • The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

06/22/2026, 1:47 PM • GlobeNewswire

5 Dividend Stocks to Buy and Hold Forever

The article highlights five blue-chip dividend stocks suitable for long-term buy-and-hold investing: AbbVie, McDonald's, Johnson & Johnson, Walmart, and Becton Dickinson. These companies have demonstrated decades of consecutive dividend increases and strong financial fundamentals, with dividends well-covered by earnings and solid growth prospects ahead.

06/22/2026, 6:15 AM • The Motley Fool

Global Hyperpigmentation Treatment Market Size to Surpass USD 2.85 Billion by 2035, Growing at a 6.5% CAGR – SNS Insider

The global hyperpigmentation treatment market is projected to grow from USD 1.52 billion in 2025 to USD 2.85 billion by 2035, expanding at a 6.5% CAGR. Growth is driven by increased consumer awareness of skin aesthetics, rising prevalence of pigmentation conditions like melasma, and adoption of advanced treatments including laser therapy and microneedling. The U.S. market is expected to reach USD 0.93 billion while Europe approaches USD 0.81 billion by 2035.

06/21/2026, 10:25 PM • GlobeNewswire

AbbVie Declares Quarterly Dividend

AbbVie Inc. declared a quarterly cash dividend of $1.73 per share, payable August 14, 2026, to stockholders of record as of July 15, 2026. The company has increased its dividend by more than 330 percent since its inception in 2013 and is a member of the S&P Dividend Aristocrats Index.

06/18/2026, 4:05 PM • Benzinga

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% overall response rate and 86% complete response rate with durable remissions and sustained MRD negativity.

06/13/2026, 12:45 PM • GlobeNewswire

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Teva Pharmaceutical has rebounded 97% in 12 months driven by its expanding biosimilars lineup and branded drugs like Austedo. However, the stock now trades at a fair 25x P/E ratio with 2026 revenue expected to be flat to lower. While biosimilars could grow to $800 million by 2027, the narrow-margin business faces intense competition and the easy gains may already be priced in. The analyst recommends watching but not buying.

06/12/2026, 4:05 PM • The Motley Fool

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients

AbbVie announced nine-year Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab significantly improved progression-free survival (6.4 years vs 3.2 years) compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients. The fixed-duration combination demonstrated median time to next treatment of 7.6 years with sustained safety and efficacy.

06/12/2026, 10:30 AM • Benzinga

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and could support future dividend growth through expanded cash flow.

06/12/2026, 6:15 AM • The Motley Fool

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

The article compares two biotech companies with contrasting profiles: Kyverna Therapeutics, a clinical-stage firm developing cell therapies for autoimmune diseases with no approved products and significant losses, versus Vertex Pharmaceuticals, an established leader generating $12 billion in revenue with a dominant cystic fibrosis franchise. The author recommends Vertex as the better 2026 investment due to its proven profitability, strong cash flow, and continued growth potential, while acknowledging Kyverna's high-risk, high-reward profile dependent on regulatory approval of its lead candidate.

06/08/2026, 2:34 PM • The Motley Fool

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress

ADARx Pharmaceuticals announced that Phase 1/2 clinical data for onvuzosiran (ADX-324), an siRNA therapeutic for hereditary angioedema (HAE), will be presented at the 2026 EAACI Annual Meeting in Istanbul. The drug is designed to reduce plasma kallikrein levels and prevent HAE attacks with reduced treatment burden. Onvuzosiran is currently in Phase 3 STOP-HAE trials and has received FDA Orphan Drug Designation.

06/08/2026, 9:00 AM • GlobeNewswire

State Street's Health Care ETF Tops Invesco's on Yield and Returns

State Street's XLV healthcare ETF outperforms Invesco's RSPH with a lower expense ratio (0.08% vs 0.4%), higher dividend yield (1.72% vs 0.7%), and better 5-year returns ($1,311 vs $1,134 on $1,000 invested). XLV uses market-cap weighting favoring large pharmaceutical companies, while RSPH employs equal-weighting for broader diversification. XLV also demonstrated greater resilience with a lower maximum drawdown over five years.

06/02/2026, 7:10 AM • The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Pfizer are compared as dividend-paying pharmaceutical giants facing patent cliffs. AbbVie shows stronger growth with $61.2B revenue (up 8.6%) and successful new product launches offsetting Humira losses, while Pfizer generated $62.6B revenue (down 1.6%) with higher dividend yield but concerns about future growth. The author recommends AbbVie for conservative investors due to its more stable business performance and predictable growth trajectory, despite Pfizer's attractive valuation metrics.

06/01/2026, 2:19 PM • The Motley Fool